Dialysis is a treatment carried out with the help of a dialyzer to remove toxins and excess fluids from a patient’s body that are formed due to the failure in the kidney functioning. This method is employed to purify the blood and to treat End-Stage Renal Disease (ESRD) and chronic renal failure. In the last few years, the prevalence of chronic renal diseases has increased significantly in Japan, which is further boosting the market growth. As per the WHO, in 2016, the prevalence of renal disorders increased by 2% compared to 2015.
The Japan dialyzer market is majorly driven by the increasing funds for the development of new and advanced products, rising healthcare expenditure, growth in disposable income, increasing prevalence of chronic diseases, and increasing geriatric population. Dialysis is one of the most preferred techniques over kidney transplantation. As per the research conducted by Dartmouth-Hitchcock, every year over 10,000 kidney transplants are performed across the globe.
For the record, the dialyzer is used in the end-stage of the renal disease and kidney transplant in which excess fluid and toxins are removed to maintain the balance between electrolytes in the blood. As per the Health Ministry of Japan, in 2016, over 10 million adults were suffering from diabetes. Some of the major reasons responsible for causing renal diseases are a sedentary lifestyle and poor diet, which is adding fuel to the market growth. Recently, the Japanese Society for Dialysis Therapy (JSDT) has proposed various clinical guidelines to maintain and provide a high level of dialysis therapy to improve the life prognosis and QOL of patients.
The Japan dialyzer market was valued at USD 473 million in 2018 and is projected to reach USD 683 million by 2026 at a CAGR of 4.6% during the forecast period 2019–2026.
The Japan dialyzer market is segmented by type, material, flux, and treatment.
Based on types, the Japan dialyzer market is segmented into parallel plate dialyzer, hollow fiber dialyzer, and others. The hollow fiber dialyzer is holding a major share of the Japan dialyzer market as it carries low blood volume. Additionally, low resistance to blood flow, well adapted for reuse, and controlled ultrafiltration are some of the other benefits offered by the technology.
Based on the flux, the Japan dialyzer market is segmented into high and low flux dialyzers. A good permeable membrane of a high flux dialyzer allows much faster fluid removal compared to the low flux. In the process of hemodiafiltration, it is essential to remove the fluid rapidly, which is further boosting the demand for high-flux dialyzers.
Based on the type of treatment, the Japan dialyzer market is segmented into hemodialysis, hemodiafiltration, and peritoneal dialysis. For the record, hemodiafiltration is a combination of hemodialysis & hemofiltration and is used in the purification of toxins for the blood. In the last five years, the market has been witnessing significant growth in the number of patients performing hemodiafiltration in Japan. As per the research, the number of patients undergoing hemodiafiltration has increased by approximately five folds in the last 3–4 years. Additionally, over 10% of the patient receiving the treatment has a history of diabetes.
Based on the material, the Japan dialyzer market is segmented into polysulfone dialyzer, polyethersulfone dialyzer, cellulose triacetate, and polypropylene dialyzers. The polysulfone material is dominating the market and is one of the most used forms of dialyzer material owing to its superior biocompatibility, lower anticoagulation requirements, ease in sterilization, and high chemical resistance and physical strength. Sometimes, it is combined with PVP to increase hydrophilicity and has the ability to retain endotoxins because of their structure. For instance, Asahi Kasei Medical Co., Ltd. offers REXEED series and ViE series Polysulfone dialyzer for hemodialysis.
In the last few years, the demand for dialyzer in Japan has increased significantly. This can be attributed to the increasing prevalence of chronic renal disease, cardiovascular disease, and diabetes, and well-developed healthcare sector. Diabetes and other cardiovascular diseases are some of the major causes of renal failure. As per the International Diabetes Federation (IDF), over 7.2 million cases of diabetes were recorded in Japan in 2017. Apart from this, increasing geriatric population is expected to fuel the demand for dialyzers in the years to come.
The results of Dialysis Outcomes and Practice Pattern Study (DOPPS) discovered that the prognosis of the patients in Japan is better than that in Europe and the U.S. This can be accredited to the increasing number of patients receiving dialysis in Japan, which has further decreased the chances of medical error to some extent.
Heart failure is one of the most common causes of death in dialysis patients and is responsible for about 24% of deaths in Japan. Patients undergoing repetitive dialysis are more prone to heart and cardiovascular diseases, which accounts for around 40% of all deaths. Moreover, increasing prevalence of chronic kidney diseases is further adding fuel to cardiovascular risks. Japan is backed with one of the best technology, which is subsequently decreasing the chance of heart death caused by heart diseases in the country.
According to the Japanese Society for Dialysis Therapy, approximately 96% of the dialysis patients in the country are on hemodialysis. Whereas, less than 4% of the patients prefer peritoneal dialysis. In recent years, the dialysis population has increased by 5.2 times, and the National Medical Care Expenditure (NMCE) has increased by 2.5 times. On the other hand, the End-Stage Renal Disease (ESRD) has increased by only 1.8 times. The drastic reduction in cost for the procedure has made the process more affordable, further creating lucrative opportunities in the Japan Dialyzer Market.
Leading companies such as NIKKISO Europe, Asahi Kasei, and Baxter are continuously working on providing technologically advanced products to sustain in the cut-throat competition. As the market in the country is grinding to a halt, there is a continuous demand for technologically advanced products and features that benefits both patients and healthcare providers.
The related medical business holds about 46% share of the Japanese market. In 2017, the sales of dialyzer grew significantly in the field of renal products. Additionally, in 2017, many Japanese companies such as Nipro Corporations expanded their medical-related segment by establishing new facilities in countries such as Ethiopia, Vietnam, China, and India, which has considerably increased the competition in Japan dialyzer market.
Today, leading players are shifting towards technological advancement to gain a competitive edge. For instance, Asahi-Kasei Corporation is offering dialyzers backed with patented unique technology. Vitamin e-coated polysulfone membrane is one such product suitable for the removal of small and low molecules weight proteins. Similarly, Tora Medical Co. Ltd is offering a wide variety of dialyzers, including Filtryzer, Filtryzer B1, and Toray Filtryzer NF, with superior biocompatibility and higher adsorption capacity.
Some of the key players in the Japan dialyzer market are Asahi Kasei Corporation (Japan), Fresenius Medical Care AG & Co. KGaA (Germany), Nikkiso Co., Ltd (Japan), Nipro Corporation (Japan), and Toray Medical Co Ltd (Japan).
Fresenius Medical Care is one of the major providers of products and services related to dialysis equipment and treatment. The company offers a wide variety of products, including dialysis machines, dialyzers, and disposable. It has established 41 robust manufacturing facilities and offers its services in over 3700 dialysis clinics across the globe. In the last few years, the healthcare services related to dialysis and care coordination have increased by 8%, while the sales of dialysis products have increased by 6%. In 2016, the company acquired NxStage Medical Inc. to expand its dialyzer business segment. Some of the major products of the company are FX CorDiax and FX classix that are equipped with one of the most-efficient middle molecule removal and effective uremic toxin removal.